Journal Article

Antifungal Antibiotics and Breakthrough Bacteremias

Richard P. Wenzel, Chris Gennings and Michael B. Edmond

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 32, issue 11, pages 1538-1539
Published in print June 2001 | ISSN: 1058-4838
Published online June 2001 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/320534
Antifungal Antibiotics and Breakthrough Bacteremias

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Patients with fever and neutropenia are at high risk for infection (∼50%) and bacteremia (∼20%). As a result, most are treated with antibacterial prophylaxis until their absolute neutrophil count exceeds 500 cells/mm3 and their temperature returns to normal. The 1997 guidelines of the Infectious Diseases Society of America suggested 1 of 3 regimens: vancomycin plus ceftazidime, monotherapy with ceftazidime or imipenem (possibly cefepime or meropenem), or dual therapy with an aminoglycoside plus an antipseudomonal β-lactam [1].

Journal Article.  1332 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.